

UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Andrew N. Ferguson, Chairman
Mark R. Meador

In the Matter of

Caremark Rx, LLC;

Zinc Health Services, LLC;

Express Scripts, Inc.;

Evernorth Health, Inc.;

Medco Health Services, Inc.;

Ascent Health Services LLC;

OptumRx, Inc.;

OptumRx Holdings, LLC; and

Emisar Pharma Services LLC,

Respondents.

Docket No. 9437

**ORDER WITHDRAWING MATTER FROM ADJUDICATION PURSUANT TO RULE
3.25(C) WITH RESPECT TO THE CAREMARK RESPONDENTS**

Complaint Counsel and Respondents Caremark Rx, LLC and Zinc Health Services LLC (collectively, the “Caremark Respondents”), having moved jointly to withdraw the matter from adjudication with respect to the Caremark Respondents for the purpose of considering a proposed consent agreement; and

Complaint Counsel and the Caremark Respondents, having submitted a proposed consent agreement containing a proposed decision and order, executed by the Caremark Respondents and by Complaint Counsel and approved by the Directors of the Bureau of Competition and Consumer Protection that, if accepted by the Commission would resolve the claims against the Caremark Respondents in their entirety (“Consent Agreement”);

IT IS ORDERED, pursuant to Rule 3.25(c) of the Commission’s Rules of Practice, 16 C.F.R. § 3.25(c), that – with respect to the Caremark Respondents – this matter be, and hereby is, withdrawn from adjudication and that all proceedings against the Caremark Respondents before the Administrative Law Judge be, and hereby are, stayed, pending a determination by the Commission with respect to the proposed Consent Agreement, pursuant to Rule 3.25(f) of the Commission’s Rules of Practice, 16 C.F.R. § 3.25(f); and

IT IS FURTHER ORDERED, pursuant to Rule 3.25(b) of the Commission’s Rules of Practice, 16 C.F.R. § 3.25(b), that the proposed Consent Agreement shall not be placed on the public record unless and until it is accepted by the Commission; and

IT IS FURTHER ORDERED, pursuant to Rule 3.25(e) of the Commission’s Rules of Practice, 16 C.F.R. § 3.25(e), that this matter shall remain in adjudicative status with respect to Respondents OptumRx, Inc., OptumRx Holdings, LLC, and Emisar Pharma Services LLC.

By the Commission.

April J. Tabor
Secretary



ISSUED: March 23, 2026